Investor actively backing innovative startups and growth-stage companies across various industries and funding rounds.
| Company Name | Founded | Funding Stage | Amount | City |
|---|---|---|---|---|
| Orbis Medicines | 2025 | Series A | $93.5M | Frederiksberg |
| Interius BioTherapeutics | 2025 | Undisclosed | $21.5M | Philadelphia |
| nChroma Bio | 2024 | Series Unknown | $75.0M | Boston |
| Replimune Group | 2024 | Post Ipo Equity | $140.0M | Woburn |
| Neurogene | 2024 | Post Ipo Equity | $200.0M | New York |
| Axonis Therapeutics | 2024 | Series A | $115.0M | Boston |
| AgomAb Therapeutics | 2024 | Series D | $88.7M | Antwerpen |
| Triveni Bio | 2024 | Series B | $115.0M | Watertown |
| 858 Therapeutics | 2024 | Series B | $50.0M | San Diego |
| Ventyx Biosciences | 2024 | Post Ipo Equity | $27.0M | San Diego |
| # | Company | Stage | Amount | Location |
|---|---|---|---|---|
| 76 | Orbis Medicines | Series A | $93.5M | Frederiksberg, Denmark |
| 77 | Interius BioTherapeutics | Undisclosed | $21.5M | Philadelphia, United States |
| 78 | nChroma Bio | Series Unknown | $75.0M | Boston, United States |
| 79 | Replimune Group | Post Ipo Equity | $140.0M | Woburn, United States |
| 80 | Neurogene | Post Ipo Equity | $200.0M | New York, United States |
| 81 | Axonis Therapeutics | Series A | $115.0M | Boston, United States |
| 82 | AgomAb Therapeutics | Series D | $88.7M | Antwerpen, Belgium |
| 83 | Triveni Bio | Series B | $115.0M | Watertown, United States |
| 84 | 858 Therapeutics | Series B | $50.0M | San Diego, United States |
| 85 | Ventyx Biosciences | Post Ipo Equity | $27.0M | San Diego, United States |
Orbis Medicines is a novel macrocyclic chemistry and computational platform for oral macrocycle drug discovery.
Interius BioTherapeutics is a biotechnology company that delivers genetic medicines for patients.
nChroma Bio is a cutting-edge biotechnology business that is developing targeted in vivo delivery systems as well as best-in-class cargo.
Replimune Group develop the next generation of ‘oncolytic immunotherapies’ for the treatment of cancer.
Neurogene is a developer of genetic medicines intended to improve patient outcomes for neurological disorders.
Axonis Therapeutics is a neuro-focused biotechnology company that focuses on the development of novel neuromedicines.
Agomab is a biotechnology company developing therapies that maintains and restores organ function in diseases characterized by fibrosis.
Triveni Bio is a a biotech company that develops functional antibodies targeting immunological and inflammatory disorders.
858 Therapeutics develops small molecule drugs targeting oncology and immunology.
Ventyx is a biopharmaceutical company focused on advancing oral therapies for patients living with autoimmune and inflammatory disorders.
GC Therapeutics uses synthetic biology to program patient-derived stem cells into various cell types in an efficient and scalable manner.
GondolaBio researches, develops and manufactures pharmaceutical products.
Navigantis empowers physicians to deliver uncompromised neurovascular care by creating a new frontier in surgical robotics.
Chemomab is a clinical-stage biotech company focusing on the discovery and development of innovative therapeutics.
Adona Medical is a technology-based company that designs and develops heart failure management systems to improve heart care.
Vigil Neuroscience is a biotechnology company that develops novel therapeutics for neurodegenerative diseases.
CARGO Therapeutics develops an adoptive cell therapy to benefit patients from potentially curative treatment options.
Stoke is developing antisense oligonucleotide medicines that target RNA splicing to increase gene expression for treatment.
Akero Therapeutics is a biotechnology company focused on reversing the NASH epidemic by restoring the body’s metabolism to a balanced state.
Clearside BioMedical is an ophthalmic company that specializes in the research, development, and commercialization of therapeutic products.
Tyra Biosciences is a biotechnology company targeting new pathways of acquired resistance in oncology with purpose-built drugs.
Longboard Pharmaceuticals delivers medicines with optimized pharmacology and pharmacokinetics to patients with rare neurological diseases.
Synnovation Therapeutics is a precision oncology company that develops therapeutics that aims to help people with cancer.
Verve Therapeutics is a clinical-stage biotechnology company developing genetic medicines for cardiovascular disease.
Harpoon Therapeutics is a clinical-stage immunotherapy company focused on the development of novel T-cell recruiting biologic therapies.
Cormorant Asset Management has invested in 134 companies tracked in our database. The portfolio spans multiple industries and funding stages, from seed-stage startups to late-stage companies.
Cormorant Asset Management's top investment sectors include Biotechnology, Health Care, Therapeutics, Medical, Pharmaceutical. The firm invests across 14 different industry categories.
Among tracked funding rounds, Akero Therapeutics received $366.9M in a Post Ipo Equity round. Cormorant Asset Management's total known invested capital is $11.5B.
Cormorant Asset Management's average investment size is $127.4M across its portfolio of 134 companies.
Recent Cormorant Asset Management portfolio additions include Orbis Medicines, Interius BioTherapeutics, nChroma Bio, Replimune Group, Neurogene. These companies were founded in 2020 or later.
Discover portfolio companies of other leading venture capital firms and investors.
View All Investors